Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic and Inflammatory Disease Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for FFAR4/GPR120 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FFAR4/GPR120 Recombinant Protein Sequence Verified. High Purity (>90% by SDS-PAGE). Purified under mild detergent conditions to preserve native transmembrane topology. |
View FFAR4 Products |
| Gene Delivery | FFAR4/GPR120 Lentivirus Premade Particles Full-length ORF for stable cell line generation. High titer, sequence verified. Ideal for functional GPCR assays. |
View FFAR4 Products |
| Benchmark Ab | Anti-FFAR4/GPR120 Benchmark Antibody Recombinant monoclonal antibody designed as a positive control for flow cytometry and surface expression validation. |
View FFAR4 Products |
| Validator | FFAR4/GPR120 siRNA Set Target-specific siRNA pool for knockdown validation in primary adipocytes or macrophages. |
View FFAR4 Products |
| Related Target A | FFAR1/GPR40 Closely related medium/long-chain fatty acid receptor. Critical for selectivity and off-target counter-screening. |
View FFAR1 Products |
| Related Target B | GLP1R Incretin receptor. FFAR4 activation in enteroendocrine L-cells synergistically stimulates GLP-1 secretion. |
View GLP1R Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Integrity of GPCRs | Lentivirus-mediated stable cell line construction preserves native 7-transmembrane structures for functional assays. |
| Selectivity Counter-Screening (FFAR1/GPR40) | Highly characterized FFAR1 and FFAR4 reference plasmids and lentiviral vectors available in parallel. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and positive control expression vectors included in the catalog. |
| False Positives in Small Molecule Screens | Target-validated siRNA pools available to confirm target-specific signaling pathways in cell-based assays. |
Live FFAR4/GPR120 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for FFAR4/GPR120 therapeutics is intensifying, with major players shifting focus from traditional non-selective fatty acid mimetics to biased agonists and small molecule modulators targeting metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes. As first-generation therapies reach the clinic, the next wave of R&D is targeting downstream G-protein vs. beta-arrestin biased signaling pathways to maximize anti-inflammatory efficacy while minimizing off-target tolerability issues.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Agonist | Metabolex, Janssen, LG Chem | Type 2 Diabetes, Obesity | Intracellular Calcium Flux & Beta-Arrestin recruitment assays (Requires Lentivirus for stable cell line generation) |
| Biased Agonist | Academic/Biotech Consortia | MASH, Inflammatory Bowel Disease | Pathway selectivity screening (Requires sequence-verified receptor variants) |
| Functional Antibodies | Preclinical Discovery Programs | Metabolic Disorders | Conformational epitope recognition (Requires native-state cell surface expression) |